FJFrank Jacobsen

Frank Jacobsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frank Jacobsen has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration

    by Elena Bady, Katharina Möller, Tim Mandelkow, Jonas B. Raedler, Cheng Yang, Julia Ebner, Magalie C.J. Lurati, Ronald Simon, Eik Vettorazzi, Franziska Büscheck, et al.

    Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.

  • Open Access

    Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker multiplexed imaging in 3098 human carcinomas reveals 6 major PD-L1-driven immune phenotypes with distinct spatial orchestration

    by Elena Bady, Katharina Moeller, Tim Mandelkow, Jonas B. Raedler, Cheng Yang, Julia Ebner, Magalie C.J. Lurati, Ronald Simon, Eik Vettorazzi, Franziska Buescheck, et al.

    Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.

  • Open Access

    Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker multiplexed imaging in 3098 human carcinomas reveals 6 major PD-L1-driven immune phenotypes with distinct spatial orchestration

    by Elena Bady, Katharina Moeller, Tim Mandelkow, Jonas B. Raedler, Cheng Yang, Julia Ebner, Magalie C.J. Lurati, Ronald Simon, Eik Vettorazzi, Franziska Buescheck, et al.

    Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.

  • Open Access

    Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration

    by Elena Bady, Katharina Möller, Tim Mandelkow, Jonas B. Raedler, Cheng Yang, Julia Ebner, Magalie C.J. Lurati, Ronald Simon, Eik Vettorazzi, Franziska Büscheck, et al.

    Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.

  • Open Access

    Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration

    by Elena Bady, Katharina Möller, Tim Mandelkow, Jonas B. Raedler, Cheng Yang, Julia Ebner, Magalie C.J. Lurati, Ronald Simon, Eik Vettorazzi, Franziska Büscheck, et al.

    Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.

  • Open Access

    Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration

    by Elena Bady, Katharina Möller, Tim Mandelkow, Jonas B. Raedler, Cheng Yang, Julia Ebner, Magalie C.J. Lurati, Ronald Simon, Eik Vettorazzi, Franziska Büscheck, et al.

    Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.

  • Open Access

    Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration

    by Elena Bady, Katharina Möller, Tim Mandelkow, Jonas B. Raedler, Cheng Yang, Julia Ebner, Magalie C.J. Lurati, Ronald Simon, Eik Vettorazzi, Franziska Büscheck, et al.

    Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.

  • Open Access

    Data from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration

    by Elena Bady, Katharina Möller, Tim Mandelkow, Jonas B. Raedler, Cheng Yang, Julia Ebner, Magalie C.J. Lurati, Ronald Simon, Eik Vettorazzi, Franziska Büscheck, et al.

    Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or limited to a small tissue size that hampers translational studies on large tissue microarray cohorts. Here we have developed a BLEACH&STAIN mfIHC method that enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate automated immune checkpoint quantification on tumor and immune cells and study its spatial interplay an artificial intelligence–based framework incorporating 17 different deep-learning systems was established. Unsupervised clustering showed that the three PD-L1 phenotypes (PD-L1+ tumor and immune cells, PD-L1+ immune cells, PD-L1−) were either inflamed or noninflamed. In inflamed PD-L1+patients, spatial analysis revealed that an elevated level of intratumoral M2 macrophages as well as CD11c+ dendritic cell (DC) infiltration (P < 0.001 each) was associated with a high CD3+ CD4± CD8± FOXP3± T-cell exclusion and a high PD-1 expression on T cells (P < 0.001 each). In breast cancer, the PD-L1 fluorescence intensity on tumor cells showed a significantly higher predictive performance for overall survival (OS; AUC, 0.72, P < 0.001) compared with the commonly used percentage of PD-L1+ tumor cells (AUC, 0.54). In conclusion, our deep-learning–based BLEACH&STAIN framework facilitates rapid and comprehensive assessment of more than 60 spatially orchestrated immune cell subpopulations and its prognostic relevance.Implications:The development of an easy-to-use high-throughput 15+1 multiplex fluorescence approach facilitates the in-depth understanding of the immune tumor microenvironment (TME) and enables to study the prognostic relevance of more than 130 immune cell subpopulations.

  • Open Access

    BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration

    by Elena Bady, Katharina Moeller, Tim Mandelkow, Jonas B. Raedler, Cheng Yang, Julia Ebner, Magalie C.J. Lurati, Ronald Simon, Eik Vettorazzi, Franziska Buescheck, et al.

    Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or limited to a small tissue size that hampers translational studies on large tissue microarray cohorts. Here we have developed a BLEACH&STAIN mfIHC method that enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate automated immune checkpoint quantification on tumor and immune cells and study its spatial interplay an artificial intelligence–based framework incorporating 17 different deep-learning systems was established. Unsupervised clustering showed that the three PD-L1 phenotypes (PD-L1+ tumor and immune cells, PD-L1+ immune cells, PD-L1−) were either inflamed or noninflamed. In inflamed PD-L1+patients, spatial analysis revealed that an elevated level of intratumoral M2 macrophages as well as CD11c+ dendritic cell (DC) infiltration (P < 0.001 each) was associated with a high CD3+ CD4± CD8± FOXP3± T-cell exclusion and a high PD-1 expression on T cells (P < 0.001 each). In breast cancer, the PD-L1 fluorescence intensity on tumor cells showed a significantly higher predictive performance for overall survival (OS; AUC, 0.72, P < 0.001) compared with the commonly used percentage of PD-L1+ tumor cells (AUC, 0.54). In conclusion, our deep-learning–based BLEACH&STAIN framework facilitates rapid and comprehensive assessment of more than 60 spatially orchestrated immune cell subpopulations and its prognostic relevance. Implications: The development of an easy-to-use high-throughput 15+1 multiplex fluorescence approach facilitates the in-depth understanding of the immune tumor microenvironment (TME) and enables to study the prognostic relevance of more than 130 immune cell subpopulations.


  • Open Access

    DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples

    by Kristina Jansen, Nagina Farahi, Franziska Büscheck, Maximilian Lennartz, Andreas M. Luebke, Eike Burandt, Anne Menz, Martina Kluth, Claudia Hube-Magg, Andrea Hinsch, et al.